PharmaCyte Biotech (PMCB) Non Operating Income (2021 - 2026)
PharmaCyte Biotech (PMCB) posted quarterly Non Operating Income of -$1.9 million for Q2 2026, down 114.71% year-over-year from $12.8 million in Q2 2025, and down 165.7% quarter-over-quarter from $2.9 million in Q1 2026.
PharmaCyte Biotech (PMCB) Non Operating Income (2021 - 2026) Analysis & Trends
PharmaCyte Biotech (PMCB) has reported Non Operating Income for 6 consecutive years, with -$1.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non Operating Income fell 114.71% year-over-year to -$1.9 million; the TTM figure through Apr 2026 stood at -$12.6 million (down 135.88% YoY), while the FY2026 annual figure was -$12.6 million, down 135.88% from the prior year.
- Non Operating Income retreated to -$1.9 million in Q2 2026 per PMCB's latest filing, from $2.9 million in the prior quarter.
- Across five years, Non Operating Income topped out at $24.7 million in Q3 2024 and bottomed at -$7.5 million in Q3 2025.
- Historically, Non Operating Income has averaged $1.9 million across 5 years, with a median of $286854.5 in 2022.
- Annual changes were most pronounced in 2022 — Non Operating Income soared 18103.61% — and 2025, when it sank 1562.15%.
- PharmaCyte Biotech's Non Operating Income stood at $438113.0 in 2022, then jumped by 858.52% to $4.2 million in 2023, then tumbled by 108.66% to -$363500.0 in 2024, then tumbled by 1562.15% to -$6.0 million in 2025, then jumped by 68.85% to -$1.9 million in 2026.
- Business Quant data shows PMCB's Non Operating Income at -$1.9 million in Q2 2026, $2.9 million in Q1 2026, and -$6.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | PharmaCyte Biotech | 4.38 Mn | 4.38 Mn | - | -1.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | -1.88 Mn |
| Jan 31, 2026 | 2.86 Mn |
| Oct 31, 2025 | -6.04 Mn |
| Jul 31, 2025 | -7.51 Mn |
| Apr 30, 2025 | 12.79 Mn |
| Jan 31, 2025 | -2.09 Mn |
| Oct 31, 2024 | -363,500.00 |
| Jul 31, 2024 | 24.69 Mn |
| Apr 30, 2024 | 4.51 Mn |
| Jan 31, 2024 | 1.25 Mn |
| Oct 31, 2023 | 4.20 Mn |
| Jul 31, 2023 | -1.11 Mn |
| Apr 30, 2023 | 776,945.00 |
| Jan 31, 2023 | 788,847.00 |
| Oct 31, 2022 | 438,113.00 |
| Jul 31, 2022 | 135,596.00 |
| Apr 30, 2022 | 84,994.00 |
| Jan 31, 2022 | 44,829.00 |
| Oct 31, 2021 | 25,097.00 |
| Jul 31, 2021 | -2,067.00 |